Figure S2. Effects of tozasertib combination therapies on cell viability as determined by MTT assay after 5 days of incubation. A) ABCB1-expressing UKF-NB-3*VCR\textsuperscript{10} were treated with tozasertib, the ABCB1 inhibitor zosuquidar, or their combination. B) Primary human foreskin fibroblasts were treated with tozasertib, the MDM2 inhibitor nutlin-3, or their combination. * P < 0.05 relative to either single treatment.